Free Trial
NYSE:JNJ

Johnson & Johnson (JNJ) Stock Price, News & Analysis

$161.40
+1.24 (+0.77%)
(As of 08/21/2024 ET)
Today's Range
$160.32
$161.48
50-Day Range
$145.40
$164.14
52-Week Range
$143.13
$167.84
Volume
5.02 million shs
Average Volume
7.31 million shs
Market Capitalization
$388.44 billion
P/E Ratio
10.06
Dividend Yield
3.07%
Price Target
$173.21

Johnson & Johnson MarketRank™ Stock Analysis

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
7.3% Upside
$173.21 Price Target
Short Interest
Healthy
0.79% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.62mentions of Johnson & Johnson in the last 14 days
Based on 38 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.76%
From $10.07 to $10.65 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.48 out of 5 stars

Medical Sector

99th out of 924 stocks

Pharmaceutical Preparations Industry

33rd out of 426 stocks

JNJ stock logo

About Johnson & Johnson Stock (NYSE:JNJ)

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.





JNJ Stock Price History

JNJ Stock News Headlines

Procter Gamble Company, PG official website homepage under magnifying glass.
4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt (JNJ)
Shield your investments from market volatility with these four resilient defensive stocks, offering stability and potential growth despite uncertainty.
Johnson and Johnson sign, logo at an American multinational corporation office
3 Defensive Stocks Weathering the Market Storm (JNJ)
Despite last week's market downturn, JNJ, KO, and PG posted gains, demonstrating resilience and potentially serving as defensive safe-haven investments.
Secure this "AI Fuel" Stock Before the Billionaires Buy It All
According to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.
Healthcare business, Medical business data growth chart. Doctor working on network with professional service, Research and development, Business investment, Medical technology and health service.
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms (JNJ)
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July.
surgical robot in operating room with surgeons
Intuitive Surgical Stock Outperforms Market: Highs on the Horizon (JNJ)
Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growing
37% Of This Johnson & Johnson Insider's Holdings Were Sold
Secure this "AI Fuel" Stock Before the Billionaires Buy It All
According to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.
J&J Gets FDA Approval of New Chemo-Free Lung Cancer Treatment
JNJ Aug 2024 142.000 call
See More Headlines
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/4 Dividend
5/20/2024
Dividend Payable
6/04/2024
Last Earnings
7/17/2024
Today
8/22/2024
Ex-Dividend for 9/10 Dividend
8/27/2024
Dividend Payable
9/10/2024
Next Earnings (Estimated)
10/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
47816010
Employees
131,900
Year Founded
1886

Price Target and Rating

Average Stock Price Target
$173.21
High Stock Price Target
$215.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+7.3%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$35.15 billion
Pretax Margin
22.53%

Debt

Sales & Book Value

Annual Sales
$86.58 billion
Cash Flow
$13.71 per share
Book Value
$29.72 per share

Miscellaneous

Outstanding Shares
2,406,679,000
Free Float
2,402,828,000
Market Cap
$388.44 billion
Optionable
Optionable
Beta
0.52

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • Johnson & Johnson reported strong quarterly earnings, beating analyst estimates, indicating a financially healthy company.
  • The company has a solid return on equity of 36.60%, showcasing efficient use of shareholder funds to generate profits.
  • Johnson & Johnson has a high net margin of 46.34%, indicating strong profitability in its operations.
  • Institutional investors have been increasing their holdings in Johnson & Johnson, reflecting confidence in the company's future performance.
  • Johnson & Johnson pays a consistent quarterly dividend with a dividend yield of 3.13%, providing investors with a steady income stream.

Cons

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Johnson & Johnson's dividend payout ratio is relatively high at 30.92%, which may limit future dividend growth or reinvestment in the business.
  • While the company has shown revenue growth, the rate of growth at 4.3% may not be sufficient for some investors seeking higher growth opportunities.
  • Market volatility and regulatory challenges in the healthcare sector could impact Johnson & Johnson's stock price and performance.
  • Competition in the healthcare industry is intense, which may pressure Johnson & Johnson's market share and profitability in the long term.
  • Investors should consider the current stock price and evaluate if it aligns with their investment objectives and risk tolerance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, August 18, 2024. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

JNJ Stock Analysis - Frequently Asked Questions

How have JNJ shares performed this year?

Johnson & Johnson's stock was trading at $156.74 at the beginning of 2024. Since then, JNJ shares have increased by 3.0% and is now trading at $161.40.
View the best growth stocks for 2024 here
.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Wednesday, July, 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson's revenue for the quarter was up 4.3% compared to the same quarter last year.
Read the conference call transcript
.

Is Johnson & Johnson doing a stock buyback?

Johnson & Johnson's Board of Directors authorized a share repurchase plan on Wednesday, September 14th 2022, which authorizes the company to buy back $5,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 1.2% of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its stock is undervalued.

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?

2,535 employees have rated Johnson & Johnson Chief Executive Officer Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among the company's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Johnson & Johnson have any subsidiaries?

The following companies are subsidiaries of Johnson & Johnson: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's top institutional shareholders include Legal & General Group Plc (0.97%), Bank of New York Mellon Corp (0.90%), Massachusetts Financial Services Co. MA (0.78%) and Ameriprise Financial Inc. (0.60%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker and James D Swanson.
View institutional ownership trends
.

How do I buy shares of Johnson & Johnson?

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC) and JPMorgan Chase & Co. (JPM).

This page (NYSE:JNJ) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners